Role of the WT1 tumor suppressor in murine hematopoiesis

被引:44
作者
Alberta, JA
Springett, GM
Rayburn, H
Natoli, TA
Loring, J
Kreidberg, JA
Housman, D
机构
[1] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[2] MIT, Dept Biol, Cambridge, MA 02139 USA
[3] MIT, Whitehead Inst, Cambridge, MA 02139 USA
[4] Childrens Hosp, Dept Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
关键词
D O I
10.1182/blood-2002-06-1656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The WT1 tumor-suppressor gene is expressed by many forms of acute myeloid leukemia. Inhibition of this expression can lead to the differentiation and reduced growth of leukemia cells and cell lines, suggesting that WT1 participates in regulating the proliferation of leukemic cells. However, the role of WT1 in normal hematopoiesis is not well understood. To investigate this question, we have used murine cells in which the WT1 gene has been inactivated by homologous recombination. We have found that cells lacking WT1 show deficits in hematopoietic stem cell function. Embryonic stem cells lacking WT1, although contributing efficiently to other organ systems, make only a minimal contribution to the hematopoietic system in chimeras, indicating that hematopoietic stem cells lacking WT1 compete poorly with healthy stem cells. In addition, fetal liver cells lacking WT1 have an approximately 75% reduction in erythroid blast-forming unit (BFU-E), erythroid colony-forming unit (CFU-E), and colony-forming unit-granulocyte macrophage-erythroid-megakaryocyte (CFU-GEMM). However, transplantation of fetal liver hematopoietic cells lacking WT1 will repopulate the hematopoietic system of an irradiated adult recipient in the absence of competition. We conclude that the absence of WT1 in hematopoietic cells leads to functional defects in growth potential that may be of consequence to leukemic cells that have alterations in the expression of WT1.
引用
收藏
页码:2570 / 2574
页数:5
相关论文
共 64 条
[41]   Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product [J].
Oka, Y ;
Elisseeva, OA ;
Tsuboi, A ;
Ogawa, H ;
Tamaki, H ;
Li, HF ;
Oji, Y ;
Kim, EH ;
Soma, T ;
Asada, M ;
Ueda, K ;
Maruya, E ;
Saji, H ;
Kishimoto, T ;
Udaka, K ;
Sugiyama, H .
IMMUNOGENETICS, 2000, 51 (02) :99-107
[42]   Cancer immunotherapy targeting Wilms' tumor gene WT1 product [J].
Oka, Y ;
Udaka, K ;
Tsuboi, A ;
Elisseeva, OA ;
Ogawa, H ;
Aozasa, K ;
Kishimoto, T ;
Sugiyama, H .
JOURNAL OF IMMUNOLOGY, 2000, 164 (04) :1873-1880
[43]  
PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677
[44]   The wilms tumour gene WT1 in leukaemia [J].
PritchardJones, K ;
KingUnderwood, L .
LEUKEMIA & LYMPHOMA, 1997, 27 (3-4) :207-&
[45]  
PritchardJones K, 1997, EXP HEMATOL, V25, P1311
[46]  
Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0
[47]  
Sako M, 1998, LEUKEMIA RES, V22, P965
[48]   WT1 proteins: functions in growth and differentiation [J].
Scharnhorst, V ;
van der Eb, AJ ;
Jochemsen, AG .
GENE, 2001, 273 (02) :141-161
[49]   Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia [J].
Schmid, D ;
Heinze, G ;
Linnerth, B ;
Tisljar, K ;
Kusec, R ;
Geissler, K ;
Sillaber, C ;
Laczika, K ;
Mitterbauer, M ;
Zochbauer, S ;
Mannhalter, C ;
Haas, OA ;
Lechner, K ;
Jager, U ;
Gaiger, A .
LEUKEMIA, 1997, 11 (05) :639-643
[50]   PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors [J].
Scott, EW ;
Fisher, RC ;
Olson, MC ;
Kehrli, EW ;
Simon, MC ;
Singh, H .
IMMUNITY, 1997, 6 (04) :437-447